Whether the clinical application of Watson biological class 1 vaccine is suspected or not

According to the information on the website of CFDA on April 27, the status of clinical application and review of meningococcal Haemophilus influenzae b polysaccharide conjugate vaccine of class 1 biological product acyw135 group under development by Watson Biology (300142 SZ) was changed to suspended due to the publication of non approval report An industry person familiar with the drug review process pointed out that not approving the publication of the report means that the drug declaration has been rejected, but in theory, the company can also take the means of appeal In response, Watson said that the company did not receive notice from CFDA According to the public information, acyw135 group meningococcal Haemophilus influenzae b polysaccharide conjugate vaccine is the first class of biological products for prevention, which is used to prevent the epidemic cerebrospinal meningitis caused by group A, C, y and W135 meningococci and the infectious diseases caused by Haemophilus influenzae b in children, such as meningitis, pneumonia, etc At present, the same vaccine products are not marketed at home and abroad In January 2013, Watson biological bulletin declared that the vaccine was accepted clinically The company pointed out that the use of combined vaccine can significantly reduce the total number of shots vaccinated compared with individual vaccinations, while reducing the vaccine shedding rate and the pain of vaccinators "The research and development of the above-mentioned combined vaccine will enrich the company's vaccine product line and improve the company's product competitiveness."